Ferric Carboxymaltose iron is the - first non-dextran iron supplement, which has the characteristics of stable activity, good water solubility and low toxicity. The main indication of its preparation - Carboxymaltose iron injection is to treat severe uterine bleeding; Iron deficiency anemia in postpartum, inflammatory enteritis and hemodialysis patients can also be used to treat iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease (nd-ckd).
The preparation of this product has been listed in many foreign countries for many years. On June 30, 2020, the original research Vivor (International) Inc. IDT biologika GmbH and Hangzhou tiger Pharmaceutical Technology Co., Ltd. applied for the original research import registration, which is under CDE review.
Sichuan Bojia Pharmaceutical Co., Ltd., founded in 2009, is located at No. 28, Shunjiang Avenue, East District, Meishan Economic Development Zone, Sichuan province, relocated and renamed from Chengdu Bojia Pharmaceutical Co., Ltd. Focusing on the research, production and sales of macromolecular APIs, we Bojia is a professional API manufacturer with drug production license, drug registration approval and GMP certificate. After years of development, we have accumulated rich experience in research, production and sales, and have excellent technical team and advanced production and testing equipment.
Our products including: plasma expander raw materials, hydroxyethyl starch 130 / 0.4 and hydroxyethyl starch 200 / 0.5; Peritoneal dialysis API Icodextrin; Raw materials of iron supplement: sucrose iron, protein iron succinate, carboxyl maltose iron and polysaccharide iron; Polypeptide APIs, such as atosiban acetate, linaclotide, teduglutide, semaglutide, etc; And dutasteride, a raw material drug for the treatment of prostate and hair loss.
Sichuan Bojia Pharmaceutical Co., Ltd
Denise 13438884871
Email:cdbojia@aliyun.com
Add: Eastern of Economic Developing Zone, Meishan City, Sichuan Province, China.
TEL/Fax: 0086 028 81716847